PMID- 22658896
OWN - NLM
STAT- MEDLINE
DCOM- 20130522
LR  - 20121008
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 12
IP  - 5
DP  - 2012 Oct
TI  - Risk stratification of plasma cell neoplasm: insights from plasma cell-specific 
      cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. 
      conventional FISH.
PG  - 366-74
LID - S2152-2650(12)00084-5 [pii]
LID - 10.1016/j.clml.2012.05.003 [doi]
AB  - We directly compared the results of routine fluorescence in situ hybridization 
      (FISH) and plasma cell-specific cytoplasmic immunoglobulin (cIg) FISH from 75 
      paired samples for myeloma risk stratification. CIg FISH improves test 
      specificity and sensitivity and tends to eliminate borderline results. It proves 
      that most plasma cells (PCs) consistently carry the abnormality in myelomas with 
      an IGH translocation, whereas routine FISH detects these cells only at variably 
      low levels. BACKGROUND: Routine cytogenetic analysis of plasma cell neoplasms 
      (PCNs) has a low sensitivity. Conventional fluorescence in situ hybridization 
      (FISH) is not plasma cell (PC) specific and results are diluted by other cells in 
      the sample. Although PC-specific FISH testing has been recommended for multiple 
      myeloma (MM) risk stratification, eg, by combining cytoplasmic immunoglobulin 
      (cIg) staining with FISH, the benefits of cIg FISH have never been directly 
      demonstrated in a controlled study. PATIENTS AND METHODS: Seventy-five samples 
      from patients with PCNs were analyzed by concomitant conventional FISH and cIg 
      FISH with probes for t(4;14), t(11;14), t(14;16), -13, 17p-, and +3. The results 
      were compared for their reliability, specificity, and consistency. RESULTS: Apart 
      from marginally improving detection threshold in samples with low PC burden, cIg 
      FISH identified more abnormal cases (50 vs. 47 cases) and more chromosome 
      abnormalities (113 vs. 103 events) than did conventional FISH. It differentiated 
      del(13q) in myelodysplasia from MM. Remarkably, cIg FISH consistently identified 
      a high percentage of abnormal PCs in all cases. It detected IGH translocation in 
      78% to 100% of PCs in all but 2 positive cases, whereas conventional FISH 
      detected 0% to 46% in these cases (median, 91% vs. 9%). The abnormal cells found 
      in patients with 17p- were 19% to 96% by cIg FISH vs. 0% to 13% by conventional 
      FISH (median, 54% vs. 9%). Cases with insufficient PCs for cIg FISH had only 
      normal conventional FISH results. CONCLUSION: CIg FISH improves reliability of 
      FISH testing for PCNs by eliminating borderline results. In myelomas with an IGH 
      translocation, myeloma cells invariably carry the abnormality.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Dong, Henry
AU  - Dong H
AD  - Esoterix Genetic Laboratories, LLC, New York, NY 10019, USA. dongy@labcorp.com
FAU - Yang, Hai-Su
AU  - Yang HS
FAU - Jagannath, Sundar
AU  - Jagannath S
FAU - Stephenson, Christine F
AU  - Stephenson CF
FAU - Brenholz, Pauline
AU  - Brenholz P
FAU - Mazumder, Amitabha
AU  - Mazumder A
FAU - Chari, Ajai
AU  - Chari A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20120601
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
RN  - 0 (Immunoglobulins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chromosome Aberrations
MH  - Cytogenetic Analysis/*methods
MH  - Cytoplasm/genetics/metabolism
MH  - Female
MH  - Humans
MH  - Immunoglobulins/*chemistry
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/diagnosis/genetics/metabolism
MH  - Neoplasms, Plasma Cell/*diagnosis/genetics/metabolism
MH  - Plasma Cells/metabolism
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Young Adult
EDAT- 2012/06/05 06:00
MHDA- 2013/05/23 06:00
CRDT- 2012/06/05 06:00
PHST- 2012/02/01 00:00 [received]
PHST- 2012/04/21 00:00 [revised]
PHST- 2012/05/03 00:00 [accepted]
PHST- 2012/06/05 06:00 [entrez]
PHST- 2012/06/05 06:00 [pubmed]
PHST- 2013/05/23 06:00 [medline]
AID - S2152-2650(12)00084-5 [pii]
AID - 10.1016/j.clml.2012.05.003 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):366-74. doi: 
      10.1016/j.clml.2012.05.003. Epub 2012 Jun 1.